Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters

被引:214
作者
Jacobs, MR
机构
[1] Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
关键词
Pharmacokinetics; pharmacodynamics; Streptococcus pneumoniae; Haemophilus influenzae; respiratory tract infection; otitis media;
D O I
10.1046/j.1198-743x.2001.00295.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To understand the relationship between drug dose and efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics need to be integrated. Patterns of antimicrobial activity fall into one of two major patterns: time-dependent killing and concentration-dependent killing. Time-dependent killing is characteristic of many antibiotic classes, such as beta -lactams and macrolides, and seeks to optimise the duration of exposure of a pathogen to an antimicrobial. The major PK/PD parameter correlating with efficacy of time-dependent antimicrobials is the serum concentration present for 40-50% of the dosing interval and this concentration is the susceptibility limit or breakpoint for the dosing regimen used. The second pattern, concentration-dependent killing, seeks to maximise antimicrobial concentration and is seen with aminoglycosides, quinolones and azalides. The major PK/PD parameter correlating with efficacy of these agents is the 24-h area under the curve to MIC ratio, which should be greater than or equal to 25 for less severe infections or in immunocompetent hosts, and greater than or equal to 100 in more severe infections or in immunocompromised hosts. PK/PD breakpoints for concentration-dependent agents can therefore be calculated from the formula AUC divided by 25, This enables development of PK/PD breakpoints based on the above parameters for time- and concentration-dependent agents for defined dosing regimens. For an antimicrobial to be useful empirically, the MIC(90)s of the agent against the common pathogens responsible for the disease being treated should be below the PK/PD breakpoint. This is particularly important for oral dosing regimens for treating emerging resistant respiratory tract pathogens, where efficacy against the predominant pathogens, Streptococcus pneumoniae and Haemophilus influenzae, is required.
引用
收藏
页码:589 / 596
页数:8
相关论文
共 29 条
  • [1] Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg BID Versus clarithromycin 500 mg BID
    Anzueto, A
    Niederman, MS
    Tillotson, GS
    [J]. CLINICAL THERAPEUTICS, 1998, 20 (05) : 885 - 900
  • [2] Community-acquired pneumonia in adults: Guidelines for management
    Bartlett, JG
    Breiman, RF
    Mandell, LA
    File, TM
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) : 811 - 838
  • [3] EFFICACY AND TOLERABILITY OF AZITHROMYCIN VERSUS AMOXICILLIN/CLAVULANIC ACID IN ACUTE PURULENT EXACERBATION OF CHRONIC-BRONCHITIS
    BEGHI, G
    BERNI, F
    CARRATU, L
    CASALINI, A
    CONSIGLI, G
    DANTO, M
    GIOIA, V
    MOLINO, A
    PAIZIS, G
    VAGHI, A
    [J]. JOURNAL OF CHEMOTHERAPY, 1995, 7 (02) : 146 - 152
  • [4] Brook I, 1996, J OTOLARYNGOL, V25, P249
  • [5] OVERVIEW OF COMMUNITY-ACQUIRED PNEUMONIA - PROGNOSIS AND CLINICAL-FEATURES
    CAMPBELL, GD
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1994, 78 (05) : 1035 - 1048
  • [6] Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis
    Chodosh, S
    McCarty, J
    Farkas, S
    Drehobl, M
    Tosiello, R
    Shan, M
    Aneiro, L
    Kowalsky, S
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) : 722 - 729
  • [7] Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
    Chodosh, S
    Schreurs, A
    Siami, G
    Barkman, HW
    Anzueto, A
    Shan, M
    Moesker, H
    Stack, T
    Kowalsky, S
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) : 730 - 738
  • [8] Craig W, 1998, HANDB EXP PHARM, V127, P207
  • [9] INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS
    CRAIG, WA
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) : 89 - 96
  • [10] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10